LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has commenced an investigation on behalf of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ: RMTI) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Rockwell Medical, Inc. investigation page on our website at https://www.glancylaw.com/case/rockwell-medical-inc-0.
On May 22, 2018, Rockwell announced that the Company’s President and Chief Executive Officer, Robert Chioini, had been terminated from his positions, effective immediately. However, on May 23, 2018, a letter to shareholders was published on behalf of Mr. Chioini explaining that Mr. Chioini had called an emergency Board meeting for the purpose of discussing alleged breaches of fiduciary duties and other possible violations of securities laws by various directors the Company, and that those directors whose conduct was the subject of the alleged breaches of fiduciary duties voted to fire Mr. Chioini.
On this news, Rockwell’s share price fell significantly, and as of, May 23, 2018, trading in the Company’s shares has been halted.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Rockwell securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.